Dublin, Oct. 17, 2016 -- Research and Markets has announced the addition of the "Central Nervous System Disorders Pipeline Database - 2016 Update" report to their offering.
Central Nervous System Disorders Pipeline Highlights Database - 2016 Update, provides most up-to-date information on key pipeline products in the global Central Nervous System (CNS) disorders Drug market. It covers emerging therapies for CNS indications in active clinical development stages including early and late stage clinical trials. Key indications covered in this database include Multiple Sclerosis, Depression, Alzheimer's disease, Parkinson's disease, ADHD, Schizophrenia, Epilepsy, Migraine, and Huntington's disease. The pipeline data is presented in an excel dashboard with filtering options.
The pipeline data presented in this database helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.
By Indication:
The database presents pipeline by CNS indications. Key indications covered in this database include Multiple Sclerosis, Depression, Alzheimer's disease, Parkinson's disease, ADHD, Schizophrenia, Epilepsy, Migraine, and Huntington's disease.
By Clinical Trial Stages:
The database provides CNS disorders pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.
By Drug Mechanism Classes:
The database provides CNS disorders pipeline products by their dominant drug mechanism class. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.
By Company:
The database provides CNS disorders pipeline products by the company.
SUMMARY:
- CNS disorders Pipeline by Indication
- CNS disorders Pipeline by Clinical Trial Phase
- CNS disorders Pipeline by Drug Mechanism Classes
- CNS disorders Pipeline by Company
For more information about this report visit http://www.researchandmarkets.com/research/68wfzs/central_nervous
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Central Nervous System Drugs


Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Instagram Outage Disrupts Thousands of U.S. Users
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 



